- Home
- GENI vs IOVA Comparison
GENI vs IOVA Comparison
Compare GENI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | IOVA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GENI | IOVA |
|---|---|---|
| Price | $6.91 | $4.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $12.75 | $9.00 |
| AVG Volume (30 Days) | 4.8M | ★ 15.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.00 | $47.74 |
| Revenue Next Year | $20.12 | $40.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $1.76 |
| 52 Week High | $13.73 | $5.64 |
Technical Indicators
Market Signals| Indicator | GENI | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 42.64 |
| Support Level | $5.55 | $3.77 |
| Resistance Level | $6.95 | $4.45 |
| Average True Range (ATR) | 0.38 | 0.42 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 59.55 | 19.95 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.